August 6, 2025 — Leads & Copy — A study published in Vaccine supports the efficacy of Appili Therapeutics’ biodefense vaccine candidate, ATI-1701, against tularemia. The research details robust protection in rat and non-human primate models following exposure to aerosolized Francisella tularensis.
ATI-1701, a live attenuated strain of F. tularensis, is being developed as a vaccine against tularemia. The study, co-authored by Dr. Carl Gelhaus and researchers from U.S., Canadian, and Swedish biodefense institutions, highlights findings from preclinical studies.
In rats challenged with aerosolized SCHU S4, survival rates reached 100% up to one year post-vaccination. Cynomolgus macaques showed up to 100% protection, reduced disease severity, and improved outcomes. Immunized animals also exhibited robust antibody responses.
ATI-1701 is positioned as a potential vaccine needed on the market. There is no approved vaccine for the prevention of tularemia in the United States or other major global markets.
ATI-1701 is a novel, live-attenuated vaccine for F. tularensis, which causes tularemia, a Category A pathogen.
Media Contact: Jenna McNeil, Communications Manager, Appili Therapeutics, E: JMcNeil@AppiliTherapeutics.com; Investor Relations Contact: Don Cilla, President and CEO, Appili Therapeutics, E: Info@AppiliTherapeutics.com
Source: Appili Therapeutics
